Subconjunctival Aflibercept for the Treatment of Formed Corneal Neovascularization.

PURPOSE To evaluate the effect of a single subconjunctival aflibercept injection on formed corneal neovascularization. METHODS A prospective clinical trial, conducted at a single tertiary medical center. Included were consecutive patients with corneal pathologies complicated by corneal neovascularization, who were candidates for anti-vascular endothelial growth factor treatment at the discretion of a cornea specialist. A single subconjunctival injection of 0.08 mL of Aflibercept (Eylea 25 mg/mL) was administered near the limbus in proximity to the areas of maximal pathological neovascularization. Follow-up visits were scheduled on days 7, 30, 60, and 90 following injection. Best-corrected visual acuity (BCVA), intraocular pressure, slitlamp examination, digital cornea photography, specular microscopy, and anterior-segment optical coherence tomography were documented at each visit. The images were graded by a masked observer for density, extent, and centricity of corneal vascularization. RESULTS Six eyes of six patients were analyzed. No clinically significant ocular or systemic adverse events were documented. No change was noted in extent, density, or centricity of corneal blood vessels at seven, 30, and 90 days after injection (P>0.1 for all time point comparisons, Friedman test). Best-corrected visual acuity fluctuated insignificantly in 5/6 patients during follow-up time, and objective but not subjective improvement of BCVA was noted in one patient with no concurrent change of neovascularization. The recruitment has therefore halted prematurely. CONCLUSIONS A single subconjunctival aflibercept injection seems to be well tolerated. However, it is ineffective for regressing formed corneal neovascularization.

[1]  Da-Wei Li Neovascularization , 2020, Definitions.

[2]  Pradeep Susvar,et al.  Subconjunctival bevacizumab and argon laser photocoagulation for preexisting neovascularization following deep lamellar anterior keratoplasty , 2019, Indian journal of ophthalmology.

[3]  I. Bahar,et al.  Comparison of Subconjunctival Aflibercept and Betamethasone for the Treatment of Formed Corneal Neovascularization in a Rabbit Model , 2019, Ophthalmic Research.

[4]  J. Reidy,et al.  Short-term regression of corneal neovascularization with combination therapy of argon green laser photocoagulation and subconjunctival bevacizumab , 2019, International medical case reports journal.

[5]  Sibel Aksoy Treatment of corneal neovascularization with topical aflibercept in a case of exposure keratopathy following cerebellar astrocytoma surgery , 2019, Indian journal of ophthalmology.

[6]  E. Holland,et al.  Current and emerging therapies for corneal neovascularization. , 2018, The ocular surface.

[7]  T. Kadar,et al.  Successful single treatment with ziv‐aflibercept for existing corneal neovascularization following ocular chemical insult in the rabbit model , 2018, Experimental eye research.

[8]  C. Cursiefen,et al.  Fine Needle-Diathermy Regresses Pathological Corneal (Lymph)Angiogenesis and Promotes High-Risk Corneal Transplant Survival , 2018, Scientific Reports.

[9]  K. Yoon,et al.  Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens–Johnson syndrome , 2019, International Ophthalmology.

[10]  T. Das,et al.  Intravitreal Ziv‐Aflibercept: Clinical Effects and Economic Impact , 2017, Asia-Pacific journal of ophthalmology.

[11]  M. Shahsuvaryan Therapeutic Potential of Ranibizumab in Corneal Neovascularization. , 2017, Trends in pharmacological sciences.

[12]  Chan Hee Moon,et al.  Comparison of Topical Low-Molecular-Weight Heparin–Taurocholate and Bevacizumab for Treatment and Prevention of Corneal Neovascularization , 2017, Cornea.

[13]  M. Kim,et al.  Effects of Combined Photodynamic Therapy and Topical Bevacizumab Treatment on Corneal Neovascularization in Rabbits , 2016, Cornea.

[14]  D. Weinberger,et al.  Efficacy of Subconjunctival Aflibercept Versus Bevacizumab for Prevention of Corneal Neovascularization in a Rat Model , 2016, Cornea.

[15]  T. B. Ali,et al.  [Management of corneal neovascularization prior to corneal transplantation: Report of 112 cases]. , 2016, Journal francais d'ophtalmologie.

[16]  D. Weinberger,et al.  Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model. , 2016, Experimental eye research.

[17]  C. Willoughby,et al.  Method for Angiographically Guided Fine-Needle Diathermy in the Treatment of Corneal Neovascularization , 2016, Cornea.

[18]  Q. Nguyen,et al.  Aflibercept for neovascular age-related macular degeneration. , 2016, The Cochrane database of systematic reviews.

[19]  K. Mireskandari,et al.  Corneal Fine Needle Diathermy With Adjuvant Bevacizumab to Treat Corneal Neovascularization in Children , 2015, Cornea.

[20]  A. Mansour,et al.  Ziv-aflibercept in macular disease , 2015, British Journal of Ophthalmology.

[21]  Chung-Tien Lin,et al.  Mechanisms Controlling the Effects of Bevacizumab (Avastin) on the Inhibition of Early but Not Late Formed Corneal Neovascularization , 2014, PloS one.

[22]  A. Loewenstein,et al.  High-Dose Topical Bevacizumab for Corneal Neovascularization , 2013, Pharmacology.

[23]  F. Parmeggiani,et al.  Aflibercept in wet AMD: specific role and optimal use , 2013, Drug design, development and therapy.

[24]  R. Dana,et al.  Topical Ranibizumab as a Treatment of Corneal Neovascularization , 2013, Cornea.

[25]  A. Galor,et al.  Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium , 2013, Clinical ophthalmology.

[26]  D. Azar,et al.  Corneal neovascularization: an anti-VEGF therapy review. , 2012, Survey of ophthalmology.

[27]  R. Forte,et al.  Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study , 2012, Cornea.

[28]  M. Stewart Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept , 2012, Clinical ophthalmology.

[29]  I. Bahar,et al.  Anterior segment uses of bevacizumab , 2012, Current opinion in ophthalmology.

[30]  J. Jeong,et al.  Compensatory Growth Factor and Cytokine Response in Tears After Subconjunctival Bevacizumab Injection , 2011, Cornea.

[31]  S. Yeung,et al.  Combined Use of Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization , 2011, Cornea.

[32]  R. Dana,et al.  Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable , 2011, British Journal of Ophthalmology.

[33]  Seungbum Kang,et al.  The Effect of Subconjuctival Combined Treatment of Bevacizumab and Triamcinolone Acetonide on Corneal Neovascularization in Rabbits , 2010, Cornea.

[34]  P. Vassileva,et al.  Avastin use in high risk corneal transplantation , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[35]  R. Dana,et al.  Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. , 2009, Archives of ophthalmology.

[36]  A. Kheirkhah,et al.  Temporary sutureless amniotic membrane patch for acute alkaline burns. , 2008, Archives of ophthalmology.

[37]  H. Tchah,et al.  The effect of topical bevacizumab on corneal neovascularization. , 2008, Ophthalmology.

[38]  I. Bahar,et al.  Subconjunctival Bevacizumab Injection for Corneal Neovascularization , 2008, Cornea.

[39]  K. Bartz-Schmidt,et al.  Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn , 2007, Acta ophthalmologica.

[40]  Björn Bachmann,et al.  Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. , 2007, Investigative ophthalmology & visual science.

[41]  D. Azar Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). , 2006, Transactions of the American Ophthalmological Society.

[42]  B. Rouse,et al.  Contribution of Vascular Endothelial Growth Factor in the Neovascularization Process during the Pathogenesis of Herpetic Stromal Keratitis , 2001, Journal of Virology.